Alto Neuroscience, Inc. (NYSE:ANRO) Receives $26.50 Consensus Target Price from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $26.50.

ANRO has been the subject of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Wall Street Zen raised shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. BTIG Research upped their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Chardan Capital increased their price target on shares of Alto Neuroscience from $15.00 to $30.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, Robert W. Baird raised their price target on shares of Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th.

Alto Neuroscience Stock Performance

ANRO opened at $22.22 on Friday. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20. The stock’s 50 day moving average price is $17.69 and its two-hundred day moving average price is $12.82. The firm has a market capitalization of $690.50 million, a P/E ratio of -9.70 and a beta of 2.52. Alto Neuroscience has a 12-month low of $1.60 and a 12-month high of $23.56.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Personalized Indexing Management LLC increased its stake in Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after acquiring an additional 2,055 shares during the period. Peapod Lane Capital LLC lifted its position in shares of Alto Neuroscience by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after acquiring an additional 3,106 shares during the period. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the 4th quarter worth approximately $62,000. XTX Topco Ltd grew its holdings in shares of Alto Neuroscience by 32.2% during the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after purchasing an additional 5,078 shares in the last quarter. Finally, Citizens Financial Group Inc. RI grew its holdings in shares of Alto Neuroscience by 19.0% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock worth $161,000 after purchasing an additional 6,394 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.